Nguyen DI et al. [131] recently published the data of 3 patients who received omalizumab (a humanized monoclonal anti-IgE antibody)-facilitated oral immunotherapy (OIT) for shrimp allergy in a multiple OIT trial. This evidence concerns the gene IGHE and allergic disease.